AUROBINDO PHARMA Financial Statement Analysis
|
||
|
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
The Earnings Per Share (EPS) of AUROBINDO PHARMA has decreased by -27.21 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
AUROBINDO PHARMA Last 5 Annual Financial Results
[BOM: 524804|NSE : AUROPHARMA]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹24,855 Cr | ₹23,455 Cr | ₹24,775 Cr | ₹23,099 Cr | ₹19,564 Cr |
| Expenses | ₹21,137 Cr | ₹19,071 Cr | ₹19,441 Cr | ₹18,234 Cr | ₹15,612 Cr |
| Operating Profit (Excl OI) | ₹3,719 Cr | ₹4,385 Cr | ₹5,333 Cr | ₹4,864 Cr | ₹3,952 Cr |
| Other Income | ₹291 Cr | ₹323 Cr | ₹381 Cr | ₹192 Cr | ₹155 Cr |
| Interest | ₹140 Cr | ₹49 Cr | ₹74 Cr | ₹305 Cr | ₹263 Cr |
| Depreciation | ₹1,245 Cr | ₹1,127 Cr | ₹1,055 Cr | ₹967 Cr | ₹668 Cr |
| Profit Before Tax | ₹2,613 Cr | ₹3,373 Cr | ₹7,344 Cr | ₹3,743 Cr | ₹3,089 Cr |
| Profit After Tax | ₹1,928 Cr | ₹2,647 Cr | ₹5,334 Cr | ₹2,844 Cr | ₹2,362 Cr |
| Consolidated Net Profit | ₹1,928 Cr | ₹2,648 Cr | ₹5,335 Cr | ₹2,845 Cr | ₹2,365 Cr |
| Earnings Per Share (Rs) | ₹32.90 | ₹45.20 | ₹91.05 | ₹48.56 | ₹40.36 |
| PAT Margin (%) | 3.79 | 5.54 | 10.98 | 6.02 | 5.89 |
| ROE(%) | 7.50 | 11.38 | 27.53 | 18.52 | 18.47 |
| ROCE(%) | 9.39 | 12.71 | 30.10 | 18.72 | 17.97 |
| Total Debt/Equity(x) | 0.18 | 0.10 | 0.23 | 0.33 | 0.50 |
Key Financials |
||
| Market Cap | : | ₹ 67,522.0 Cr |
| Revenue (TTM) | : | ₹ 27,894.7 Cr |
| Net Profit(TTM) | : | ₹ 2,777.9 Cr |
| EPS (TTM) | : | ₹ 47.4 |
| P/E (TTM) | : | 24.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AUROBINDO PHARMA | 6.4% | 7.7% | 87.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.1% | -6.6% | 56.7% |
| CIPLA | 0.2% | -4.4% | 54.3% |
| DR REDDYS LABORATORIES | 4.3% | 2.6% | 29.9% |
| ZYDUS LIFESCIENCES | 2.2% | -4.6% | 86.6% |
| DIVIS LABORATORIES | 4.8% | 18.9% | 23.9% |
| MANKIND PHARMA | -1.4% | 1.4% | NA |
| TORRENT PHARMACEUTICALS | -1.7% | 3% | 65.8% |
| LUPIN | 4.1% | 3% | 131.2% |
AUROBINDO PHARMA Revenues
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | 5.97 % |
| 5 Yr CAGR | 6.17 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹24,855 Cr | 5.97 | |
| Mar2022 | ₹23,455 Cr | -5.32 | |
| Mar2021 | ₹24,775 Cr | 7.26 | |
| Mar2020 | ₹23,099 Cr | 18.07 | |
| Mar2019 | ₹19,564 Cr | - | |
AUROBINDO PHARMA Operating Profit
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | -15.19 % |
| 5 Yr CAGR | -1.51 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,719 Cr | -15.19 | |
| Mar2022 | ₹4,385 Cr | -17.79 | |
| Mar2021 | ₹5,333 Cr | 9.64 | |
| Mar2020 | ₹4,864 Cr | 23.09 | |
| Mar2019 | ₹3,952 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -19.96 % |
| 5 Yr CAGR | -7.23 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 14.96% | -19.96 | |
| Mar2022 | 18.69% | -13.19 | |
| Mar2021 | 21.53% | 2.23 | |
| Mar2020 | 21.06% | 4.26 | |
| Mar2019 | 20.2% | - | |
AUROBINDO PHARMA Profit After Tax
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | -27.21 % |
| 5 Yr CAGR | -4.98 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,928 Cr | -27.21 | |
| Mar2022 | ₹2,648 Cr | -50.36 | |
| Mar2021 | ₹5,335 Cr | 87.51 | |
| Mar2020 | ₹2,845 Cr | 20.32 | |
| Mar2019 | ₹2,365 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -31.59 % |
| 5 Yr CAGR | -10.44 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 3.79 % | -31.59 | |
| Mar2022 | 5.54 % | -49.54 | |
| Mar2021 | 10.98 % | 82.39 | |
| Mar2020 | 6.02 % | 2.21 | |
| Mar2019 | 5.89 % | - | |
AUROBINDO PHARMA Earnings Per Share (EPS)
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | -27.21 % |
| 5 Yr CAGR | -4.98 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹33 | -27.21 | |
| Mar2022 | ₹45 | -50.36 | |
| Mar2021 | ₹91 | 87.50 | |
| Mar2020 | ₹49 | 20.32 | |
| Mar2019 | ₹40 | - | |
AUROBINDO PHARMA Return on Capital Employed (ROCE)
[BOM: 524804|NSE : AUROPHARMA]
| Y-o-Y | -26.12 % |
| 5 Yr CAGR | -14.98 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 9.39% | -26.12 | |
| Mar2022 | 12.71% | -57.77 | |
| Mar2021 | 30.1% | 60.79 | |
| Mar2020 | 18.72% | 4.17 | |
| Mar2019 | 17.97% | - | |
AUROBINDO PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,152.5 |
| Current MarketCap | : | ₹ 67,522.0 Cr |
| Updated EOD on | : | Apr 30,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AUROBINDO PHARMA | 6.4% |
7.7% |
87.6% |
| SENSEX | 1% |
2.8% |
23.9% |
AUROBINDO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MOMENTUM | 4.3% | 8% | 83.3% |
| S&P BSE MID CAP | 3.8% | 7.8% | 68.7% |
| S&P BSE 150 MIDCAP | 3.3% | 7.5% | 60.9% |
| S&P BSE 400 MIDSMALLCAP | 2.9% | 8.6% | 62.4% |
| S&P BSE MIDSMALLCAP | 2.7% | 9.3% | 67.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY200 MOMENTUM 30 INDEX | 4.4% | 6.8% | 71.9% |
| NIFTY HEALTHCARE | 2.9% | 0.7% | 52.1% |
| NIFTY MIDCAP 50 | 2.8% | 5.1% | 60.7% |
| NIFTY PHARMA | 2.8% | 0.9% | 52.3% |
| NIFTY MIDCAP150 | 2.6% | 7% | 61.1% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA Financials
How the annual revenues of AUROBINDO PHARMA have changed ?
The Revenues of AUROBINDO PHARMA have increased by 5.97% YoY .
How the Earnings per Share (EPS) of AUROBINDO PHARMA have changed?
The Earnings Per Share (EPS) of AUROBINDO PHARMA has decreased by -27.21 % YoY .
Check out Intrinsic Value of Peers of AUROBINDO PHARMA
Compare Stock Analytics of Peers of AUROBINDO PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
